請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/60838完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 楊銘欽(Ming-Chin Yang) | |
| dc.contributor.author | Yu-Jen Shen | en |
| dc.contributor.author | 沈祐任 | zh_TW |
| dc.date.accessioned | 2021-06-16T10:32:28Z | - |
| dc.date.available | 2020-08-26 | |
| dc.date.copyright | 2020-08-26 | |
| dc.date.issued | 2020 | |
| dc.date.submitted | 2020-07-03 | |
| dc.identifier.citation | Anderson, J. R., Armitage, J. O., Weisenburger, D. D., Non-Hodgkins Lymphoma Classificat, P. (1998). Epidemiology of the non-Hodgkin's lymphomas: Distributions of the major subtypes differ by geographic locations. Annals of Oncology, 9(7), 717-720. doi:10.1023/a:1008265532487 Becker, U., Briggs, A. H., Moreno, S. G., Ray, J. A., Ngo, P., Samanta, K. (2016). Cost-Effectiveness Model for Chemoimmunotherapy Options in Patients with Previously Untreated Chronic Lymphocytic Leukemia Unsuitable for Full-Dose Fludarabine-Based Therapy. Value in Health, 19(4), 374-382. doi:10.1016/j.jval.2015.12.018 Anderson, J. R., Armitage, J. O., Weisenburger, D. D., Non-Hodgkins Lymphoma Classificat, P. (1998). Epidemiology of the non-Hodgkin's lymphomas: Distributions of the major subtypes differ by geographic locations. Annals of Oncology, 9(7), 717-720. doi:10.1023/a:1008265532487 Becker, U., Briggs, A. H., Moreno, S. G., Ray, J. A., Ngo, P., Samanta, K. (2016). Cost-Effectiveness Model for Chemoimmunotherapy Options in Patients with Previously Untreated Chronic Lymphocytic Leukemia Unsuitable for Full-Dose Fludarabine-Based Therapy. Value in Health, 19(4), 374-382. doi:10.1016/j.jval.2015.12.018 Binet, J. L., Auquier, A., Dighiero, G., Chastang, C., Piguet, H., Goasguen, J., . . . Gremy, F. (1981). A NEW PROGNOSTIC CLASSIFICATION OF CHRONIC LYMPHOCYTIC-LEUKEMIA DERIVED FROM A MULTIVARIATE SURVIVAL ANALYSIS. Cancer, 48(1), 198-206. doi:10.1002/1097-0142(19810701)48:1<198::Aid-cncr2820480131>3.0.Co;2-v Blommestein, H. M., de Groot, S., Aarts, M. J., Vemer, P., de Vries, R., van Abeelen, A. F. M., . . . Uyl-de Groota, C. A. (2016). Cost-effectiveness of obinutuzumab for chronic lymphocytic leukaemia in The Netherlands. Leukemia Research, 50, 37-45. doi:10.1016/j.leukres.2016.09.005 Byrd, J. C., Furman, R. R., Coutre, S. E., Flinn, I. W., Burger, J. A., Blum, K. A., . . . O'Brien, S. (2013). Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia. New England Journal of Medicine, 369(1), 32-42. doi:10.1056/NEJMoa1215637 Chan, W. C., Armitage, J. O., Gascoyne, R., Connors, J., Close, P., Jacobs, P., . . . Roy, P. (1997). A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. Blood, 89(11), 3909-3918. Retrieved from <Go to ISI>://WOS:A1997XD37900002 Deans, J. P., Polyak, M. J. (2008). FMC7 is an epitope of CD20. Blood, The Journal of the American Society of Hematology, 111(4), 2492-2492. Dighiero, G. (1997). Chronic lymphocytic leukemia treatment. In: Springer. Dighiero, G., Travade, P., Chevret, S., Fenaux, P., Chastang, C., Binet, J.-L. (1991). B-cell chronic lymphocytic leukemia: present status and future directions. Blood, 78(8), 1901-1914. Gale, R. P. (1987). Chronic Lymphocytic Leukemia: Recent Progress and Future Direction, pages 411-418© 1987 Alan R. Liss, Inc. Paper presented at the Chronic lymphocytic leukemia: recent progress and future direction: proceedings of a Hyland Laboratories-UCLA Symposium held in Napa, California, December 2-5, 1986. Goede, V., Fischer, K., Busch, R., Engelke, A., Eichhorst, B., Wendtner, C. M., . . . Hallek, M. (2014). Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions. New England Journal of Medicine, 370(12), 1101-1110. doi:10.1056/NEJMoa1313984 Goede, V., Fischer, K., Engelke, A., Schlag, R., Lepretre, S., Montero, L. F. C., . . . Hallek, M. (2015). Obinutuzumab as frontline treatment of chronic lymphocytic leukemia: updated results of the CLL11 study. Leukemia, 29(7), 1602-1604. doi:10.1038/leu.2015.14 Hallek, M. (2015). Chronic lymphocytic leukemia: 2015 Update on diagnosis, risk stratification, and treatment. American Journal of Hematology, 90(5), 446-460. doi:10.1002/ajh.23979 Hernandez, J., Nielsen, T., Klein, C., Wenger, M. (2018). Obinutuzumab for the treatment of non-Hodgkin lymphomas. Nature, 563(7731), 3. Retrieved from <Go to ISI>://WOS:000450048400009 Keating, G. M. (2010). Rituximab. Drugs, 70(11), 1445-1476. Keating, M. J. (1999). Improving the complete remission rate in chronic lymphocytic leukemia. Kipps, T. J., Stevenson, F. K., Wu, C. J., Croce, C. M., Packham, G., Wierda, W. G., . . . Rai, K. (2017). Chronic lymphocytic leukaemia. Nature Reviews Disease Primers, 3, 21. doi:10.1038/nrdp.2016.96 Kosmas, C. E., Shingler, S. L., Samanta, K., Wiesner, C., Moss, P. A. H., Becker, U., Lloyd, A. J. (2015). Health state utilities for chronic lymphocytic leukemia: importance of prolonging progression-free survival. Leukemia Lymphoma, 56(5), 1320-1326. doi:10.3109/10428194.2014.961012 Lanasa, M. C. (2010). Novel insights into the biology of CLL. Hematology 2010, the American Society of Hematology Education Program Book, 2010(1), 70-76. Marcus, R., Davies, A., Ando, K., Klapper, W., Opat, S., Owen, C., . . . Seymour, J. F. (2017). Obinutuzumab for the first-line treatment of follicular lymphoma. New England Journal of Medicine, 377(14), 1331-1344. Marcus, R., Sweetenham, J. W., Williams, M. E. (2013). Lymphoma: pathology, diagnosis, and treatment: Cambridge University Press. Matutes, E., Owusu-Ankomah, K., Morilla, R., Garcia Marco, J., Houlihan, A., Que, T., Catovsky, D. (1994). The immunological profile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL. Leukemia, 8(10), 1640-1645. McLaughlin, P., Grillo-Lopez, A. J., Link, B. K., Levy, R., Czuczman, M. S., Williams, M. E., . . . Dallaire, B. K. (1998). Rituximab chimeric Anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program. Journal of Clinical Oncology, 16(8), 2825-2833. doi:10.1200/jco.1998.16.8.2825 Palumbo, G. A., Parrinello, N., Fargione, G., Cardillo, K., Chiarenza, A., Berretta, S., . . . Di Raimondo, F. (2009). CD200 expression may help in differential diagnosis between mantle cell lymphoma and B-cell chronic lymphocytic leukemia. Leukemia Research, 33(9), 1212-1216. Paquete, A. T., Miguel, L. S., Becker, U., Pereira, C., Pinto, C. G. (2017). Cost-Effectiveness Analysis of Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukaemia in Portuguese Patients who are Unsuitable for Full-Dose Fludarabine-Based Therapy. Applied Health Economics and Health Policy, 15(4), 501-512. doi:10.1007/s40258-017-0321-2 Plosker, G. L., Figgitt, D. P. (2003). Rituximab. Drugs, 63(8), 803-843. Rai, K. R., Sawitsky, A., Cronkite, E. P., Chanana, A. D., Levy, R. N., Pasternack, B. S. (1975). CLINICAL STAGING OF CHRONIC LYMPHOCYTIC LEUKEMIA. Blood, 46(2), 219-234. doi:10.1182/blood.V46.2.219.219 Robak, P., Smolewski, P., Robak, T. (2015). Emerging immunological drugs for chronic lymphocytic leukemia. Expert Opin Emerg Drugs, 20(3), 423-447. doi:10.1517/14728214.2015.1046432 Rozman, C., Montserrat, E. (1995). CURRENT CONCEPTS - CHRONIC LYMPHOCYTIC-LEUKEMIA. New England Journal of Medicine, 333(16), 1052-1057. doi:10.1056/nejm199510193331606 Shanshal, M., Haddad, R. Y. (2012). Chronic Lymphocytic Leukemia. Dm Disease-a-Month, 58(4), 153-167. doi:10.1016/j.disamonth.2012.01.009 Sinha, R., Redekop, W. K. (2018). Cost-Effectiveness of Ibrutinib Compared With Obinutuzumab With Chlorambucil in Untreated Chronic Lymphocytic Leukemia Patients With Comorbidities in the United Kingdom. Clinical Lymphoma Myeloma Leukemia, 18(2), E131-E142. doi:10.1016/j.clml.2017.12.005 Tepper, J. E., Niederhuber, J. O., Armitage, J. H., Doroshow, M. B., Kastan, J. E. (2014). Childhood lymphoma. Vardiman, J. W., Thiele, J., Arber, D. A., Brunning, R. D., Borowitz, M. J., Porwit, A., . . . Bloomfield, C. D. (2009). The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood, 114(5), 937-951. doi:10.1182/blood-2009-03-209262 Weiner, G. J. (2010). Rituximab: mechanism of action. Paper presented at the Seminars in hematology. Wild, C. P., Stewart, B. W., Wild, C. (2014). World cancer report 2014: World Health Organization Geneva, Switzerland. Wu, S. J., Huang, S. Y., Lin, C. T., Lin, Y. J., Chang, C. J., Tien, H. F. (2010). The incidence of chronic lymphocytic leukemia in Taiwan, 1986-2005: a distinct increasing trend with birth-cohort effect. Blood, 116(22), 4430-4435. doi:10.1182/blood-2010-05-285221 Yagudina, R., Kulikov, A., Babiy, V. V. (2015). COST-EFFECTIVENESS ANALYSIS OF OBINUTUZUMAB/CHLORAMBUCIL VS RITUXIMAB/CHLORAMBUCIL IN TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA. Value in Health, 18(7), A460-A460. doi:10.1016/j.jval.2015.09.1186 Zare, H., Bashashati, A., Kridel, R., Aghaeepour, N., Haffari, G., Connors, J. M., . . . Weng, A. P. (2012). Automated analysis of multidimensional flow cytometry data improves diagnostic accuracy between mantle cell lymphoma and small lymphocytic lymphoma. American journal of clinical pathology, 137(1), 75-85. Zwiebel, J. A., Cheson, B. D. (1998). Chronic lymphocytic leukemia: staging and prognostic factors. Paper presented at the Seminars in oncology. | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/60838 | - |
| dc.description.abstract | 目的：本研究使用衛生福利部中央健康保險署之觀點，利用經濟評估方法比較台灣晚期CD20陽性之慢性淋巴球白血病患者接受單株抗體Obinutuzumab併用化學治療藥物Chlorambucil (G-CLB) 治療策略相較於株抗體Rituximab併用化學治療藥物Chlorambucil (R-CLB) 治療策略之成本效用。
方法：由2014至2016年之全民健康保險研究資料庫兩百萬抽樣歸人檔獲得晚期慢性淋巴球白血病患者之真實資料，統計分析後得到病患接受治療之疾病無惡化存活期與疾病惡化存活期之醫療成本，並使用文獻回顧取得疾病無惡化存活期（Progression-Free Survival, PFS）、整體存活期（Overall Survival, OS）、風險比值（Hazard ratio, HR）與各項健康狀態之健康效用值(Utilities)，最後以馬可夫模型模擬20年之慢性淋巴球白血病病患使用新治療策略G-CLB及R-CLB治療藥物組合策略之成本差異後，進行成本效用分析及多維敏感度分析，計算遞增成本效果比值（Incremental Cost-Effectiveness Ratio, ICER）。 結果：晚期CD20陽性之慢性淋巴球白血病患者病患使用G-CLB治療策略相對R-CLB治療策略，LYs增加0.55，QUALYs增加0.36，且遞增成本效果比值(ICER)分別為-231,252.95與-359,036.58，低於成本效用閾值，即代表G-CLB相較於R-CLB為具有優勢之治療模式，且使用G-CLB治療策略可用較低之成本得到較佳之治療效果。 | zh_TW |
| dc.description.abstract | Objective: The study aimed to estimate the cost-utility of Obinutuzumab treatment (G-CLB) as first-line medication on Chronic Lymphocytic Leukemia (CLL) patients comparing to Rituximab treatment (R-CLB) from the payer’s perspective in Taiwan. Methods: A cost-utility analysis was conducted using a Markov model from the National Health Insurance Administrative perspective. Real-world data and costs were obtained from National Health Insurance Research Database to calculate the maintenance cost of progression-free survival health state and progression survival health state of late stage CLL patients using chemotherapy as main treatment strategy. On the other hand, progression-free survival, overall survival, hazard ratios, and utilities of each health states obtained from literature review were used to simulate the survival conditions separately for late stage CD20 positive CLL patients using G-CLB treatment or R-CLB treatment. Results: Compared to R-CLB treatment, late-stage CD20 positive CLL patients using G-CLB treatment as first-line medication resulted in gaining 0.55 life-years (LYs) and 0.36 quality-adjusted life-years (QALYs),yielding ICER values of -231,252.95 and -359,036.58, respectively. The results sugest that G-CLB are dominant treatment stragege when compared to R-CLB. | en |
| dc.description.provenance | Made available in DSpace on 2021-06-16T10:32:28Z (GMT). No. of bitstreams: 1 U0001-0207202010283600.pdf: 5547791 bytes, checksum: c56ac8e8fd5c701b5df12c0cc5ade11c (MD5) Previous issue date: 2020 | en |
| dc.description.tableofcontents | 誌謝 i 摘要 ii Abstract iii 表目錄 vi 圖目錄……………………………………………………….…vii 第一章 緒論 1 第一節 研究背景 1 第二節 研究目的 4 第三節 研究重要性 6 第二章 文獻探討 7 第一節 慢性淋巴性白血病概述與現況 7 第二節 CD-20單株抗體藥物研究 12 第三節 Obinutuzumab 與Rituximab藥物經濟評估研究 16 第四節 綜合討論 20 第三章 研究方法 26 第一節 研究目的與對象 26 第二節 研究架構 28 第三節 資料來源與選樣流程 30 第四節 統計方法與模型參數 32 第五節 變項支操作型定義 35 第六節 成本效用分析 38 第四章 研究結果 41 第一節 健保資料描述性統計結果 41 第二節 成本效用分析 46 第三節 敏感度分析(Sensitivity analysis) 48 第五章 討論 61 第一節 研究方法 61 第二節 重要發現 64 第三節 研究限制 67 第六章 結論與建議 70 第一節 結論 70 第二節 建議 71 | |
| dc.language.iso | zh-TW | |
| dc.subject | 慢性淋巴球白血病 | zh_TW |
| dc.subject | 醫療費用 | zh_TW |
| dc.subject | 成本效用分析 | zh_TW |
| dc.subject | Medical cost | en |
| dc.subject | Obinutuzumab | en |
| dc.subject | Rituximab | en |
| dc.subject | Chronic Lymphocytic Leukemia | en |
| dc.subject | Cost-utility analysis | en |
| dc.title | 臺灣晚期CD20陽性慢性淋巴球性白血病患者使用Obinutuzumab 加 Chlorambucil 相較於Rituximab 加 Chlorambucil作為第一線藥物之成本效用分析 | zh_TW |
| dc.title | Cost-effectiveness of Obinutuzumab plus Chlorambucil compares with Rituximab plus Chlorambucil for the first-line treatment of late-stage Chronic Lymphocytic Leukemia patients in Taiwan | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 108-2 | |
| dc.description.degree | 碩士 | |
| dc.contributor.oralexamcommittee | 柯博升(BOR-SHENG KO),譚家惠(Chia-Hui Tan) | |
| dc.subject.keyword | 慢性淋巴球白血病,醫療費用,成本效用分析, | zh_TW |
| dc.subject.keyword | Chronic Lymphocytic Leukemia,Obinutuzumab,Rituximab,Medical cost,Cost-utility analysis, | en |
| dc.relation.page | 78 | |
| dc.identifier.doi | 10.6342/NTU202001262 | |
| dc.rights.note | 有償授權 | |
| dc.date.accepted | 2020-07-06 | |
| dc.contributor.author-college | 公共衛生學院 | zh_TW |
| dc.contributor.author-dept | 健康政策與管理研究所 | zh_TW |
| 顯示於系所單位： | 健康政策與管理研究所 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| U0001-0207202010283600.pdf 未授權公開取用 | 5.42 MB | Adobe PDF |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。